1. ACCF/AHA Pocket Guideline Management of Patients With Atrial Fibrillation (Adapted from the 2006 ACC/AHA/ESC Guideline and the 2011 ACCF/AHA/HRS Focused Updates) 2. ©…

1. ALKALOIDS 2. OBJECTIVES To know what are the characteristics ofalkaloids To know the different sources of alkaloids To determine the importance of alkaloids and…

1. Mr. A.R.Surana Assistant professor S.M.B.T. College of Pharmacy, Nashik-422403 9/6/2013 2. Definition: the term “alkaloid” (alkali-like) is commonly used to designate…

imaj 5.18_low_Full.pdf20 2018 Background: Limited information exists about detailed clinical characteristics and management of the small subset of Brugada syndrome (BrS)

Review: Clinical Trial Outcomes CLI 4 6 549 554 2014 Dextromethorphan/quinidine (DM/Q; NUEDEXTA) is approved by the US FDA for the treatment of pseudobulbar affect (PBA)

Pseudobulbar Affect among Study participants with Traumatic Brain Injury: Results from the PRISM-II Open Label Study Flora M. Hammond,1 William Sauve,2 Fred Ledon,3 Charles

Circulation is available at www.ahajournals.org/journal/circ Correspondence to: Sami Viskin, MD, Department of Cardiology, Tel Aviv Sourasky Medical Center, Weizman 6, Tel

Quinidine: an "Endangered Species" Drug Appropriate for Management of Electrical Storm in Brugada Syndrome Stelios Paraskevaidis MD, PhD, Efstratios K. Theofilogiannakos